Regeneron and Zai Lab to develop and commercialize REGN1979 in China
Category: #headlines  By Pankaj Singh  Date: 2020-04-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regeneron and Zai Lab to develop and commercialize REGN1979 in China

American biotechnology company Regeneron Pharmaceuticals is reportedly collaborating with Chinese biopharmaceutical firm Zai Lab Limited to develop and commercialize REGN1979 in mainland China, Taiwan, Hong Kong, and Macau.

REGN1979 is an advanced bispecific monoclonal antibody designed by Regeneron. It is developed to link and activate a lymphoma cell to a cytotoxic T-cell, triggering tumor killing.

As per terms of the deal, Regeneron will receive an upfront payment of US$30 million and will be eligible for an additional US$160 million in regulatory and sales milestones. Zai Lab will bear the expenses pertaining to global development of REGN1979 for several trials.

According to sources familiar with the matter, Regeneron will manufacture and supply REGN1979 for development and commercialization across regions. Zai Lab will obtain rights to develop and commercialize REGN1979 in mainland China, Taiwan, Macau, and Hong Kong. In addition, the company will also pay Regeneron depending upon net sales.

The partnership will foster the global clinical development of REGN1979, beginning with the current phase-2 trial in B-cell non-Hodgkin lymphoma (B-NHL). If approved, Zai Lab will commercialize REGN1979 in these regions.

With its regulatory and clinical expertise along with a notable commercial footprint in, Zai Lab could contribute substantially towards the success of REGN1979.

Also read: QIAGEN deploys QIAstat-Dx Respiratory SARS-CoV-2 test kits in Europe

Regeneron is renowned for its research, development and innovation in medical science, commented Samantha Du, Ph.D., founder, chairperson, and CEO of Zai Lab, adding that the company looks forward to working with the Regeneron group on REGN1979 as it expands its oncology franchise into hematologic cancers.

In collaboration with Regeneron, Zai Lab will look to expand its global effort and deliver innovative solutions to patients, Du added.

Zai Lab, according to Israel Lowy, M.D., Ph.D., Senior VP of Regeneron, is an ideal partner for Regeneron with an outstanding track record which aligns with Regeneron’s mission to leverage the power of science and deliver innovative medical products. Zai Lab will not only help boost the enrolment of REGN1979 into global trials but will also allow this promising investigational drug to reach patients faster, if approved, Lowy said.

 

Source: http://www.zailaboratory.com/in1/index.aspx

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with...

Read More

More News By Pankaj Singh

Telia rolls out commercial 5G in Stockholm powered by Ericsson RAN
Telia rolls out commercial 5G in Stockholm powered by Ericsson RAN
By Pankaj Singh

Swedish communications giants Telia and Ericsson have successfully partnered on several 5G projects, including the launch of Sweden’s first live 5G network at the KTH Royal Institute of Technology in December 2018 and a partnership with Volvo t...

KKR to acquire 2.32% stake in Reliance Jio for INR 11,367 crore
KKR to acquire 2.32% stake in Reliance Jio for INR 11,367 crore
By Pankaj Singh

Reliance Industries has recently confirmed that the private equity firm KKR has planned to invest INR 11,367 crore into Jio Platforms for acquiring a 2.32% stake. This would be the fifth significant deal announced by the Indian conglomerate over the ...

Nokia enters 5G solutions supply deal with Taiwan Star Telecom
Nokia enters 5G solutions supply deal with Taiwan Star Telecom
By Pankaj Singh

Finnish telecom equipment maker Nokia has reportedly bagged a new 5G deal from Taiwan Star Telecom (TST). As per the deal, Nokia will supply its end-to-end AirScale Radio Access Network (RAN) portfolio. The RAN portfolio will help TST to deploy non-...